Výsledky vyhledávání - "Austin, Poole"

Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma

Autor: Nicholas J. Vogelzang, Austin Poole, Wei Gao, Xiting Cao, Lixian Jin, Derek H. Tang, Barbara Ratto, Elyse Swallow, Shoba Ravichandran

Publikováno v: Clinical Genitourinary Cancer. 18:e37-e45

Introduction In the first-line (1L) setting, pazopanib (PAZ) has been recommended by the National Comprehensive Cancer Network for the treatment of advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy became a commonly used 1L

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::684c89957b90d9bb5099a12d3b9bf676
https://doi.org/10.1016/j.clgc.2019.10.010

Zobrazit plný text záznamu

Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC)

Autor: James M. Farnham, Neeraj Agarwal, Sara Wilson, Lisa A. Cannon-Albright, Andrew W. Hahn, Benjamin L. Maughan, David Gill, Robert A. Stephenson, Roberto Nussenzveig, Austin Poole

Publikováno v: Molecular Cancer Therapeutics. 18:726-729

There are many treatment options available for men with metastatic castration-resistant prostate cancer (mCRPC). Yet, biomarkers predictive of differential response to treatment are currently unavailable. A recent translational study suggested that S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a3fc6eadd63d95609c451666a1d0390
https://doi.org/10.1158/1535-7163.mct-18-0739

Zobrazit plný text záznamu

Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer

Autor: Eric D. Johnson, Neeraj Agarwal, Kenneth M. Boucher, Roberto Nussenzveig, Benjamin L. Maughan, Emma Carroll, Austin Poole, David Gill, Andrew W. Hahn

Publikováno v: Clinical Genitourinary Cancer. 16:e169-e172

Background Antiandrogen withdrawal syndrome (AAWS), manifested as a prostate-specific antigen (PSA) decline after discontinuation of a first-generation antiandrogen has been well characterized. The objective of the present study was to assess the inc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c313a335924d5aec813d6b4fd36f8a
https://doi.org/10.1016/j.clgc.2017.08.017

Zobrazit plný text záznamu

Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors

Autor: Srinivas K. Tantravahi, David D. Stenehjem, Sumanta K. Pal, Austin Poole, Shiven B. Patel, Archana M. Agarwal, Joseph Merriman, Julia A. Batten, Erin B. Bailey, Neeraj Agarwal, Benjamin L. Maughan

Publikováno v: Journal of Oncology Pharmacy Practice. 24:190-197

Purpose Hand-foot syndrome is a common dose limiting toxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors used for treatment of patients with metastatic renal cell carcinoma. The effect of treatment dose reductions, in t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6125c76ba86f22ec3a37200a4487a1a9
https://doi.org/10.1177/1078155217693426

Zobrazit plný text záznamu

Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib

Autor: Srinivas K. Tantravahi, Austin Poole, Frederic Clayton, Nicole Girard

Publikováno v: Leukemia & Lymphoma. 58:1258-1261

Hemophagocytic lymphohistiocytosis (HLH) is a rare and life threatening disorder characterized by excessive immune activation with resulting tissue injury [1]. Ibrutinib is an irreversible inhibito...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ca86d6023d1c9f1d60d56e4d8485ae17
https://doi.org/10.1080/10428194.2016.1243679

Zobrazit plný text záznamu

Germline Variant in

Autor: Andrew W, Hahn, David M, Gill, Austin, Poole, Roberto H, Nussenzveig, Sara, Wilson, James M, Farnham, Robert A, Stephenson, Lisa A, Cannon-Albright, Benjamin L, Maughan, Neeraj, Agarwal

Publikováno v: Molecular cancer therapeutics. 18(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c60112ce5ad469b6d0d27a3ae19dbe0b
https://pubmed.ncbi.nlm.nih.gov/30587554

Zobrazit plný text záznamu

Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors

Autor: Erin B. Bailey, Austin Poole, Neeraj Agarwal, David D. Stenehjem, Julia A. Batten, Chesley E. Wells, Archana M. Agarwal, Alli M. Straubhar, Srinivas K. Tantravahi, Shiven B. Patel

Publikováno v: Clinical Genitourinary Cancer. 13:e131-e137

Background Hypothyroidism is a common adverse effect of vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy in patients with metastatic renal cell carcinoma (mRCC). Some studies have shown an association with imp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417890bdef9b08da8872f8f28a21eb9d
https://doi.org/10.1016/j.clgc.2014.11.002

Zobrazit plný text záznamu

Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma

Autor: Lixian Jin, Barbara Ratto, Shoba Ravichandran, Elyse Swallow, Nicholas J. Vogelzang, Derek H. Tang, Xiting Cao, Austin Poole, Wei Gao

Publikováno v: Journal of Clinical Oncology. 37:573-573

573 Background: In the first-line setting (1L), pazopanib (PAZ) is recommended by NCCN for treatment of advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy became commonly used 1L treatment option for aRCC. This study reports

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82b67dc1228bdd214673da10708fe8b8
https://doi.org/10.1200/jco.2019.37.7_suppl.573

Zobrazit plný text záznamu

Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions

Autor: Shilpa Gupta, David Gill, Neeraj Agarwal, Austin Poole

Publikováno v: Cancers, Vol 9, Iss 2, p 15 (2017)
Cancers

Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6c392e0b9f6a6235edbd9d21f532daa
http://www.mdpi.com/2072-6694/9/2/15

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání